Published in J Pathol on February 17, 2012
Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. Int J Cancer (2012) 1.21
Papillomaviruses: Viral evolution, cancer and evolutionary medicine. Evol Med Public Health (2015) 1.13
Human papillomavirus molecular biology and disease association. Rev Med Virol (2015) 1.09
A case of HPV-53-related cervical cancer in an elderly patient. Clin Interv Aging (2014) 1.04
Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol (2013) 1.01
Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. Virol J (2013) 0.95
HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes Control (2014) 0.88
Comparison of HPV DNA testing in cervical exfoliated cells and tissue biopsies among HIV-positive women in Kenya. Int J Cancer (2013) 0.87
Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection. Papillomavirus Res (2015) 0.86
High prevalence of hpv multiple genotypes in women with persistent chlamydia trachomatis infection. Infect Agent Cancer (2014) 0.85
Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infect Dis (2015) 0.84
No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis (2013) 0.83
Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer (2013) 0.82
Concurrence of multiple human papillomavirus infections in a large US population-based cohort. Am J Epidemiol (2014) 0.82
Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM. Mod Pathol (2015) 0.80
Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections. PLoS One (2013) 0.80
Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31-65. Gynecol Oncol (2014) 0.79
Residual disease and HPV persistence after cryotherapy for cervical intraepithelial neoplasia grade 2/3 in HIV-positive women in Kenya. PLoS One (2014) 0.79
E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. PLoS One (2012) 0.79
The overexpression of p16 is not a surrogate marker for high-risk human papilloma virus genotypes and predicts clinical outcomes for vulvar cancer. BMC Cancer (2016) 0.78
Evaluating HPV-negative CIN2+ in the ATHENA trial. Int J Cancer (2016) 0.77
Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer (2016) 0.76
Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions. BMJ Open (2015) 0.76
Oncogenic human papillomaviruses. Philos Trans R Soc Lond B Biol Sci (2017) 0.75
Comparison of methods using paraffin-embedded tissues and exfoliated cervical cells to evaluate human papillomavirus genotype attribution. Cancer Sci (2016) 0.75
Assessing the detection of human papillomavirus late mRNA in liquid base cytology samples for risk stratification of cervical disease. J Med Virol (2013) 0.75
Deep sequencing of HPV E6/E7 genes reveals loss of genotypic diversity and gain of clonal dominance in high-grade intraepithelial lesions of the cervix. BMC Genomics (2017) 0.75
Food webs in the human body: linking ecological theory to viral dynamics. PLoS One (2012) 0.75
Detection of Human Papillomavirus Infections at the Single-Cell Level. Intervirology (2016) 0.75
Infectious disease: The natural history of HPV infection in men. Nat Rev Urol (2015) 0.75
Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia. Int J Cancer (2016) 0.75
Human papillomavirus 16 is an aetiological factor of scrotal cancer. Br J Cancer (2017) 0.75
WHOLE-GENOME SEQUENCING AND VARIANT ANALYSIS OF HPV16 INFECTIONS. J Virol (2017) 0.75
Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile. BMC Cancer (2017) 0.75
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity (2007) 3.38
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol (2006) 3.34
PP2A: the expected tumor suppressor. Curr Opin Genet Dev (2005) 2.91
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol (2002) 2.73
Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology (2003) 2.39
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine (2006) 2.37
Circulatory arrest versus cerebral perfusion during pulmonary endarterectomy surgery (PEACOG): a randomised controlled trial. Lancet (2011) 2.27
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One (2013) 2.03
Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology (2007) 1.94
Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol (2002) 1.94
Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol (2003) 1.92
Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol (2008) 1.85
Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol (2003) 1.79
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin (2009) 1.75
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol (2008) 1.68
Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg (2011) 1.66
Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol (2002) 1.66
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health (2007) 1.63
Assessment of human papillomavirus in lung tumor tissue. J Natl Cancer Inst (2011) 1.59
Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer (2003) 1.57
Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination. Hum Vaccin Immunother (2012) 1.55
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol (2009) 1.49
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer (2012) 1.48
Oncogenic human papillomavirus-infected immature metaplastic cells and cervical neoplasia. Am J Surg Pathol (2014) 1.46
Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine (2008) 1.43
Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res (2014) 1.42
G2/M cell cycle arrest in the life cycle of viruses. Virology (2007) 1.39
The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy. J Low Genit Tract Dis (2015) 1.39
Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer (2013) 1.38
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine (2008) 1.35
Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J (2005) 1.35
Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycle. J Virol (2005) 1.32
Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology (2011) 1.30
Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis (2009) 1.29
Evaluation of a novel highly sensitive, broad-spectrum PCR-reverse hybridization assay for detection and identification of beta-papillomavirus DNA. J Clin Microbiol (2006) 1.29
An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochem J (2004) 1.22
Identification and functional analysis of two Ca2+-binding EF-hand motifs in the B"/PR72 subunit of protein phosphatase 2A. J Biol Chem (2003) 1.21
The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/PCR methodology: results from a global study. Am J Surg Pathol (2013) 1.21
Identification of a G(2) arrest domain in the E1 wedge E4 protein of human papillomavirus type 16. J Virol (2002) 1.21
Betapapillomaviruses frequently persist in the skin of healthy individuals. J Gen Virol (2007) 1.21
Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf (2014) 1.21
Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. Cancer Res (2003) 1.20
RISC-target interaction: cleavage and translational suppression. Biochim Biophys Acta (2008) 1.18
The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo. J Virol (2004) 1.18
Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer (2011) 1.14
Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control (2009) 1.14
Polyphosphate kinase from activated sludge performing enhanced biological phosphorus removal. Appl Environ Microbiol (2002) 1.13
The protein phosphatase 2A phosphatase activator is a novel peptidyl-prolyl cis/trans-isomerase. J Biol Chem (2005) 1.11
Helicobacter pylori mutants defective in RuvC Holliday junction resolvase display reduced macrophage survival and spontaneous clearance from the murine gastric mucosa. Infect Immun (2003) 1.11
A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J (2004) 1.10
Functional analysis of the human papillomavirus type 16 E1=E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization. J Virol (2004) 1.10
Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes. J Virol (2005) 1.10
Human papillomavirus and the long-term risk of cervical neoplasia. Am J Epidemiol (2002) 1.08
Excitation of rat colonic afferent fibres by 5-HT(3) receptors. J Physiol (2002) 1.07
The Papworth experience with the Levitronix CentriMag ventricular assist device. J Heart Lung Transplant (2008) 1.05
Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): Trial design. Contemp Clin Trials (2006) 1.05
Protein phosphatase 2A on track for nutrient-induced signalling in yeast. Mol Microbiol (2002) 1.05
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother (2014) 1.05
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Polyphosphate kinase genes from full-scale activated sludge plants. Appl Microbiol Biotechnol (2007) 1.04
Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol (2009) 1.04
Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol (2003) 1.04
Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev (2009) 1.03
The biology of papillomavirus latency. Open Virol J (2012) 1.03
Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. Virology (2011) 1.02
Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. Hum Vaccin Immunother (2013) 1.02
Comprehensive control of human papillomavirus infections and related diseases. Vaccine (2013) 1.02
Genomic organisation, chromosomal localisation tissue distribution and developmental regulation of the PR61/B' regulatory subunits of protein phosphatase 2A in mice. J Mol Biol (2004) 1.01
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis (2013) 1.00
Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. Respir Med (2007) 1.00
Detection and genotyping of human rotavirus VP4 and VP7 genes by reverse transcriptase PCR and reverse hybridization. J Clin Microbiol (2009) 1.00
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. Int J Gynecol Cancer (2013) 1.00
E1 empty set E4 protein of human papillomavirus type 16 associates with mitochondria. J Virol (2004) 0.99
Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica. J Infect Dis (2013) 0.99
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health (2010) 0.97
Etiological role of human papillomavirus infection for inverted papilloma of the bladder. J Med Virol (2011) 0.97
Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol (2012) 0.97
Human Beta-papillomavirus infection and keratinocyte carcinomas. J Pathol (2015) 0.97
Sunlight exposure and (sero)prevalence of epidermodysplasia verruciformis-associated human papillomavirus. J Invest Dermatol (2004) 0.96
Digestive and physiologic effects of a wheat bran extract, arabino-xylan-oligosaccharide, in breakfast cereal. Nutrition (2012) 0.96